Ideal Candidates for Tesofensine Therapy While Tesofensine is not yet FDA-approved for any indication, ongoing research suggests that it may hold promise as a potential treatment option for individuals with obesity who have not achieved significant weight reduction through lifestyle modifications alone
But theoretical possibility is a long way from scientific evidence
Kim, S.H., Abbasi, F., & Reaven, G.M
Bartels GL, Remme WJ, Pillay M, et al
This comprehensive view reveals that the medication represents 70 to 85 percent of total costs, but the remaining 15 to 30 percent still amounts to $1,000 to $3,000 annually
Prior to this, vitamin E (800 IU daily) has shown histologic benefit in non-diabetic, biopsy-proven NASH patients in clinical trials, though long-term safety concerns exist including potential increased risks of hemorrhagic stroke and prostate cancer in men